The Muenzer MPS Research & Treatment Center is proud to share recent national coverage from NBC News highlighting the U.S. Food and Drug Administration’s approval of a new treatment for children with Hunter syndrome (MPS II).
This milestone marks an important step forward for the MPS community, particularly in advancing care for individuals affected by the neurologic manifestations of the disease.
The article features insight from Kim Stephens, DBA, Executive Director of the Muenzer MPS Research & Treatment Center, along with Joseph Muenzer, MD, PhD, Director of the Muenzer MPS Center and Bryson Distinguished Professor, whose decades of leadership and research have helped shape the field.
“This is an important step forward for patients and families affected by Hunter syndrome, particularly as we continue working toward addressing the neurologic aspects
of the disease,” said Dr. Muenzer.
While this approval represents meaningful progress, it also underscores the continued need for research, innovation, and expanded access to therapies for individuals living with MPS.
We are grateful to the patients, families, researchers, and advocates who continue to drive progress forward.
🔗 Read the full NBC News article:
https://www.nbcnews.com/health/health-news/rare-disease-hunter-syndrome-fda-approval-children-rcna265813